AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	9.86	17.76	29.66	47.04	58.51	59.65
Short-Term Investments	314.52	343.95	252.61	280.78	312.54	331.47
Trading Asset Securities	68.55	4	5	3.02	-	4
Cash & Short-Term Investments	392.93	365.71	287.27	330.84	371.05	395.12
Cash Growth	52.83%	27.30%	-13.17%	-10.84%	-6.09%	-12.66%
Accounts Receivable	10.16	20.66	11.35	4.51	5.78	2.76
Other Receivables	0.02	0.01	-	0.06	0.13	1.71
Receivables	10.18	20.66	11.35	4.57	5.91	4.47
Inventory	29.31	30.09	25.02	23.33	21.24	21.73
Prepaid Expenses	0.91	1.28	2.07	1.02	2.03	0.29
Other Current Assets	0.85	0.34	0.18	0.12	0.31	0.51
Total Current Assets	434.18	418.09	325.89	359.88	400.54	422.12
Property, Plant & Equipment	79.29	82.92	82.71	79.81	88.23	81
Long-Term Investments	62.8	125.68	28.06	28.74	34.47	52.44
Goodwill	-	31.18	31.18	31.18	31.18	31.18
Other Intangible Assets	63.31	35.15	42.5	50.54	58.62	66.76
Other Long-Term Assets	1.77	1.87	2.3	3.72	2.72	3.05
Total Assets	641.34	694.87	512.65	553.86	615.75	656.55
Accounts Payable	1.8	2.74	1.95	1.06	1.15	1.55
Current Portion of Leases	3.28	5.15	4.4	3.88	4.42	2.04
Current Unearned Revenue	0.44	0.51	2.05	2.67	5.45	32.63
Other Current Liabilities	12.19	16.75	16.02	19.75	15.11	11.5
Total Current Liabilities	17.71	25.14	24.42	27.36	26.13	47.71
Long-Term Leases	3.91	5.72	9.99	6.43	10.31	2.22
Long-Term Unearned Revenue	-	-	-	-	-	4.43
Other Long-Term Liabilities	0.32	0.29	0.29	0.29	0.28	7.08
Total Liabilities	21.93	31.16	34.7	34.08	36.72	61.44
Common Stock	633.33	633.33	532.56	532.21	532.21	532.21
Additional Paid-In Capital	141.82	141.52	8.02	95.74	94.92	94.38
Retained Earnings	-229.05	-199.32	-148.74	-192.06	-138.57	-117.86
Comprehensive Income & Other	-13.99	-6.88	-11.25	-11.32	-5.59	-11.02
Total Common Equity	532.1	568.65	380.58	424.58	482.98	497.7
Minority Interest	87.31	95.07	97.37	95.2	96.06	97.4
Shareholders' Equity	619.41	663.72	477.95	519.78	579.03	595.1
Total Liabilities & Equity	641.34	694.87	512.65	553.86	615.75	656.55
Total Debt	7.19	10.87	14.39	10.31	14.73	4.25
Net Cash (Debt)	385.75	354.84	272.88	320.53	356.32	390.87
Net Cash Growth	58.35%	30.03%	-14.87%	-10.04%	-8.84%	-11.60%
Net Cash Per Share	6.18	6.15	5.13	6.02	6.70	7.35
Filing Date Shares Outstanding	64.44	63.33	53.26	53.22	53.22	53.22
Total Common Shares Outstanding	64.44	63.33	53.26	53.22	53.22	53.22
Working Capital	416.48	392.94	301.47	332.52	374.41	374.4
Book Value Per Share	8.26	8.98	7.15	7.98	9.07	9.35
Tangible Book Value	468.8	502.33	306.9	342.87	393.18	399.76
Tangible Book Value Per Share	7.27	7.93	5.76	6.44	7.39	7.51
Land	-	52.94	52.94	52.94	52.94	52.94
Buildings	-	8.14	8.14	8.14	8.14	8.14
Machinery	-	15.57	25.15	48.47	47.34	44.92
Leasehold Improvements	-	-	-	0.82	0.82	1.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.